ConductScience.org, home

Paper36484006

Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.

Zhao J and 4 others. J Cancer, 2022. Cited by 13 papers, by iCite.

Cite this record

ConductScience Library. Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review. Papers, record 36484006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36484006

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.
PubMed
Journal
J Cancer
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
13
iCite
Relative citation ratio, by iCite
0.9
iCite
Revised in PubMed
2022-12-10
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhao JJian
2Zhang YYuehua
3Qin SSiyuan
4Zou BBingwen
5Wang YYongsheng

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References69

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122101430Natural killer cells act as rheostats modulating antiviral T cells.Nature2011https://conductscience.org/library/papers/22101430PubMed
227156385Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission.Immunity2016https://conductscience.org/library/papers/27156385PubMed
323775956Ipilimumab administration in patients with advanced melanoma and hepatitis B and C.J Clin Oncol2013https://conductscience.org/library/papers/23775956PubMed
432278215Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients.Lung Cancer2020https://conductscience.org/library/papers/32278215PubMed
525642417CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.Front Oncol2014https://conductscience.org/library/papers/25642417PubMed
632863270Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.J Immunother Cancer2020https://conductscience.org/library/papers/32863270PubMed
732547550Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.Front Immunol2020https://conductscience.org/library/papers/32547550PubMed
826541610Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science2015https://conductscience.org/library/papers/26541610PubMed
930347289Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.Eur J Cancer2018https://conductscience.org/library/papers/30347289PubMed
1026121644Doxorubicin Activates Hepatitis B Virus Replication by Elevation of p21 (Waf1/Cip1) and C/EBPα Expression.PLoS One2015https://conductscience.org/library/papers/26121644PubMed
1129156044Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.J Infect Dis2017https://conductscience.org/library/papers/29156044PubMed
1228751160M4IDP, a zoledronic acid derivative, induces G1 arrest, apoptosis and autophagy in HCT116 colon carcinoma cells via blocking PI3K/Akt/mTOR pathway.Life Sci2017https://conductscience.org/library/papers/28751160PubMed
1324367534Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing.PLoS One2013https://conductscience.org/library/papers/24367534PubMed
1425789969T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance.Cell Death Dis2015https://conductscience.org/library/papers/25789969PubMed
1523548749PD-1 coinhibitory signals: the link between pathogenesis and protection.Semin Immunol2013https://conductscience.org/library/papers/23548749PubMed
1625491730The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.Expert Opin Ther Targets2015https://conductscience.org/library/papers/25491730PubMed
1731753012Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition.J Immunother Cancer2019https://conductscience.org/library/papers/31753012PubMed
1830565239What did we learn from CTLA-4 insufficiency on the human immune system?Immunol Rev2019https://conductscience.org/library/papers/30565239PubMed
1928434648Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017https://conductscience.org/library/papers/28434648PubMed
2029406396Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.Melanoma Res2018https://conductscience.org/library/papers/29406396PubMed

See all 69 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.

PMIDTitleJournalYearIn PapersSource
42125666Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection- immunity-cancer crosstalk.Front Immunol2026https://conductscience.org/library/papers/42125666PubMed
41743730HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management.Front Immunol2026https://conductscience.org/library/papers/41743730PubMed
41183666Antineoplastic agents-associated hepatitis B virus reactivation: Research progress and molecular mechanisms.Virus Res2025https://conductscience.org/library/papers/41183666PubMed
40762016Neoadjuvant immunotherapy for resectable primary liver cancer (Review).Oncol Lett2025https://conductscience.org/library/papers/40762016PubMed
40196369
Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials.
Front Pharmacol2025https://conductscience.org/library/papers/40196369PubMed
39853863Drug-Induced Liver Injury Associated With Emerging Cancer Therapies.Liver Int2025https://conductscience.org/library/papers/39853863PubMed
39796705Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives.Cancers (Basel)2024https://conductscience.org/library/papers/39796705PubMed
39717542Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies.Front Cell Infect Microbiol2024https://conductscience.org/library/papers/39717542PubMed
38948476Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database.Front Pharmacol2024https://conductscience.org/library/papers/38948476PubMed
38721408Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors.J Immunother Precis Oncol2024https://conductscience.org/library/papers/38721408PubMed
37226111
Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials.
BMC Cancer2023https://conductscience.org/library/papers/37226111PubMed
37168999The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB.Front Pharmacol2023https://conductscience.org/library/papers/37168999PubMed

Download CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36484006

GET https://conductscience.org/api/papers/v1/36484006/references?page=2